시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 성장호르몬 결핍증 시장 규모, 점유율, 성장 분석 : 유형별, 진단별, 치료별, 투여 경로별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)
Growth Hormone Deficiency Market Size, Share, and Growth Analysis, By Type, By Diagnosis, By Treatment, By Route of Administration, By End User, By Region - Industry Forecast 2025-2032
상품코드 : 1701016
리서치사 : SkyQuest
발행일 : 2025년 04월
페이지 정보 : 영문 219 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,710,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 9,020,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 10,329,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

성장호르몬 결핍증 시장 규모는 2023년 37억 달러, 2024년 39억 달러에서 2032년 59억 9,000만 달러로 성장하고, 예측 기간(2025-2032년) 동안 5.5%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.

유전자 질환, 뇌 손상, 특정 치료 등의 요인으로 인해 성장호르몬 결핍증(GHD)의 발병률이 증가함에 따라 성장호르몬 치료에 대한 수요가 크게 증가하고 있습니다. 미국 국립생물공학정보센터(NCBI)의 자료에 따르면, 영국에서는 약 3,500-4,000명 중 1명이 소아 GHD를 앓고 있어 효과적인 치료법에 대한 수요가 증가하고 있습니다. 이러한 유병률 증가로 인해 업계가 성장하고 있으며, 그 선두에는 강력한 연구 개발이 있습니다.2022년 2월 화이자와 OPKO가 주 1회 투여하는 NGENLA(TM)(somatrogon) 주사제의 유럽연합(EU) 판매 승인을 받은 것은 성장 호르몬 치료의 성장호르몬 치료의 전망에 있어 중요한 이정표이자 업계의 성장 궤도를 더욱 견고히 하는 계기가 되었습니다.

목차

서론

조사 방법

주요 요약

시장 역학과 전망

주요 시장 인사이트

성장호르몬 결핍증 시장 규모 : 유형별

성장호르몬 결핍증 시장 규모 : 진단별

성장호르몬 결핍증 시장 규모 : 치료별

성장호르몬 결핍증 시장 규모 : 투여 경로별

성장호르몬 결핍증 시장 규모 : 최종사용자별

성장호르몬 결핍증 시장 규모 : 유통 채널별

성장호르몬 결핍증 시장 규모

경쟁 정보

주요 기업 개요

결론과 제안

LSH
영문 목차

영문목차

Growth Hormone Deficiency Market size was valued at USD 3.7 billion in 2023 and is poised to grow from USD 3.9 billion in 2024 to USD 5.99 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The rising incidence of growth hormone deficiency (GHD), driven by factors like genetic disorders, brain injuries, and specific medical treatments, is significantly boosting the demand for growth hormone therapies. Data from the National Center for Biotechnology Information (NCBI) indicates that approximately 1 in every 3,500-4,000 children in the UK is affected by pediatric GHD, highlighting a growing need for effective treatments. This increasing prevalence is catalyzing industry expansion, with robust research and development at the forefront. A notable advancement occurred in February 2022 when Pfizer and OPKO received European Union marketing authorization for their Once-Weekly NGENLA(TM) (somatrogon) Injection, marking an important milestone in the growth hormone therapy landscape and further cementing the industry's growth trajectory.

Top-down and bottom-up approaches were used to estimate and validate the size of the Growth Hormone Deficiency market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Growth Hormone Deficiency Market Segments Analysis

Global Growth Hormone Deficiency Market is segmented by Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel and region. Based on Type, the market is segmented into Pediatric Growth Hormone Deficiency and Adult Growth Hormone Deficiency. Based on Diagnosis, the market is segmented into Blood Tests, Imaging Tests, Computerized tomography (CT) scans, Magnetic resonance imaging (MRI) and Others. Based on Treatment, the market is segmented into Pharmacological Therapy, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts, and Surgery. Based on Route of Administration, the market is segmented into Intravenous, Intramuscular and Others. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Growth Hormone Deficiency Market

One of the key market drivers for the global growth hormone deficiency market is the increasing prevalence of growth hormone deficiency and related disorders among children and adults. This rise is partly attributed to better diagnosis and awareness, leading to earlier identification and treatment. Additionally, lifestyle factors, such as sedentary habits and rising obesity rates, contribute to hormonal imbalances, further fueling the need for growth hormone therapies. As healthcare providers continue to emphasize the importance of addressing growth issues and improving quality of life, the demand for effective growth hormone treatments is expected to grow significantly in the coming years.

Restraints in the Growth Hormone Deficiency Market

The market for Growth Hormone Deficiency faces significant restraints, primarily due to the high costs associated with Human Growth Hormone (HGH) therapy. This financial burden limits accessibility for various patient groups and places considerable strain on healthcare systems. A 2022 medical journal study highlighted the extensive financial challenges faced by patients and healthcare providers alike, emphasizing the need for more affordable treatment options. Addressing these economic hurdles is crucial for enhancing access to HGH therapy, prompting calls for the development of cost-effective solutions and pricing reforms to ensure that more individuals can benefit from necessary treatments without extreme financial hardship.

Market Trends of the Growth Hormone Deficiency Market

The Growth Hormone Deficiency (GHD) market is experiencing a noteworthy shift driven by innovative advancements in drug delivery systems. The introduction of wearable patches, needle-free devices, and autoinjectors enhances patient convenience and compliance, transforming how growth hormone therapies are administered. Additionally, the rise of long-acting formulations and implantable devices allows for extended-release options, significantly reducing the frequency of dosing. These innovations not only improve treatment efficacy but also elevate patient experiences, enabling wider accessibility to essential therapies. As the industry embraces these developments, the GHD market is set for robust growth, highlighting significant opportunities for pharmaceutical companies and healthcare providers alike.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Growth Hormone Deficiency Market Size by Type & CAGR (2025-2032)

Global Growth Hormone Deficiency Market Size by Diagnosis & CAGR (2025-2032)

Global Growth Hormone Deficiency Market Size by Treatment & CAGR (2025-2032)

Global Growth Hormone Deficiency Market Size by Route of Administration & CAGR (2025-2032)

Global Growth Hormone Deficiency Market Size by End User & CAGR (2025-2032)

Global Growth Hormone Deficiency Market Size by Distribution Channel & CAGR (2025-2032)

Global Growth Hormone Deficiency Market Size & CAGR (2025-2032)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기